Trials / Not Yet Recruiting
Not Yet RecruitingNCT05897138
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
A Phase 2, Multi-Center, Single Arm Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
Detailed description
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle | Drug: Lenvatinib Capsules administered orally once daily Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-06-01
- Completion
- 2027-06-01
- First posted
- 2023-06-09
- Last updated
- 2023-06-13
Source: ClinicalTrials.gov record NCT05897138. Inclusion in this directory is not an endorsement.